Literature DB >> 30799083

A novel method for stabilizing microRNA mimics.

Takuto Nogimori1, Kazuya Furutachi1, Koichi Ogami1, Nao Hosoda1, Shin-Ichi Hoshino2.   

Abstract

MicroRNAs (miRNAs) are a class of small non-coding RNAs that negatively regulate gene expression at post-transcriptional level via translational repression and/or mRNA degradation. miRNAs are associated with many cellular processes, and down-regulation of miRNAs causes numerous diseases including cancer, neurological disorders, inflammation, and cardiovascular diseases, for which miRNA replacement therapy has emerged as a promising approach. This approach aims to restore down-regulated miRNAs using synthetic miRNA mimics. However, it remains a critical issue that miRNA mimics are unstable and transient in cells. Here, we first show that miRNA mimics are rapidly degraded by a mechanism different from Tudor-staphylococcal/micrococcal-like nuclease (TSN)-mediated miRNA decay, which degrades endogenous miRNAs, and newly identified 2'-5'-oligoadenylate synthetase (OAS)/RNase L as key factors responsible for the degradation of miRNA mimics in human cells. Our results suggest that the OAS1 recognizes miRNA mimics and produces 2'-5'-oligoadenylates (2-5A), which leads to the activation of latent endoribonuclease RNase L to degrade miRNA mimics. A small-molecule inhibitor that blocks RNase L can stabilize miRNA mimics. These findings provide a promising method for the stabilization of miRNA mimics, as well as for the efficient miRNA replacement therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Curcumin; Oligoadenylate synthetase; RNase L; miRNA mimics

Year:  2019        PMID: 30799083     DOI: 10.1016/j.bbrc.2019.02.075

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Fission Impossible: Stabilized miRNA-Based Analogs in Neurodegenerative Disease.

Authors:  Walter J Lukiw
Journal:  Front Neurosci       Date:  2022-05-03       Impact factor: 5.152

2.  A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis.

Authors:  Maurizio Chioccioli; Subhadeep Roy; Rachel Newell; Linda Pestano; Brent Dickinson; Kevin Rigby; Jose Herazo-Maya; Gisli Jenkins; Steward Ian; Gauri Saini; Simon R Johnson; Rebecca Braybrooke; Guying Yu; Maor Sauler; Farida Ahangari; Shuizi Ding; Joseph DeIuliis; Nachelle Aurelien; Rusty L Montgomery; Naftali Kaminski
Journal:  EBioMedicine       Date:  2022-10-17       Impact factor: 11.205

Review 3.  Surveillance of Tumour Development: The Relationship Between Tumour-Associated RNAs and Ribonucleases.

Authors:  Nadezhda Mironova; Valentin Vlassov
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

Review 4.  MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application.

Authors:  Linsey J F Peters; Jürgen Floege; Erik A L Biessen; Joachim Jankowski; Emiel P C van der Vorst
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

Review 5.  The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.

Authors:  Jiulue Hu; Jelena Stojanović; Saman Yasamineh; Pooneh Yasamineh; Sathish Kumar Karuppannan; Mohammed Junaid Hussain Dowlath; Hamed Serati-Nouri
Journal:  Arch Virol       Date:  2021-07-19       Impact factor: 2.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.